review · Clinical Microbiology Reviews
Streptococcus pneumoniae relies on its polysaccharide capsule for virulence and survival. While pneumococcal conjugate vaccines have reduced disease caused by targeted strains, they have driven an increase in non-vaccine serotypes. Advances in serotyping, bioinformatics surveillance, and analytical tools have led to the discovery of numerous new capsule types between 2007 and 2024. These developments have also enabled the revision and de-novo determination of chemical structures for established serotypes. In addition, related non-pneumococcal Mitis-group bacteria have been found to express capsules biochemically and serologically similar to those of pneumococci. These structural and epidemiological shifts directly affect bacterial identification, carriage monitoring, and capsule classification. Tracking these changes is essential to inform the design of next-generation vaccines and maintain protection against shifting bacterial populations.
Pneumococcal infections remain a serious global health threat. As current vaccines suppress specific bacterial variants, other strains emerge to take their place. Clarifying the full diversity of bacterial capsules and identifying cross-reactive species ensures that medical surveillance remains accurate. This ongoing monitoring is crucial for healthcare planners and researchers working to update immunisation programmes and prevent disease outbreaks caused by newly dominant or newly discovered strains.
The structural data and surveillance insights directly inform vaccine manufacturers and diagnostics developers formulating next-generation pneumococcal conjugate vaccines and carriage detection assays. Because the work focuses on structural characterisation and epidemiological review from discoveries spanning 2007 to 2024, translation into reformulated commercial vaccines or diagnostic kits represents an early- to mid-stage development pathway requiring extensive formulation and clinical trial evaluation.
AI-generated from the published abstract. Always read the original work before citing.
SUMMARY<i>Streptococcus pneumoniae</i> (the "pneumococcus") is a significant human pathogen. The key determinant of pneumococcal fitness and virulence is its ability to produce a protective polysaccharide (PS) capsule, and anti-capsule antibodies mediate serotype-specific opsonophagocytic killing of bacteria. Notably, immunization with pneumococcal conjugate vaccines (PCVs) has effectively reduced the burden of disease caused by serotypes included in vaccines but has also spurred a relative upsurge in the prevalence of non-vaccine serotypes. Recent advancements in serotyping and bioinformatics surveillance tools coupled with high-resolution analytical techniques have enabled the discovery of numerous new capsule types, thereby providing a fresh perspective on the dynamic pneumococcal landscape. This review offers insights into the current pneumococcal seroepidemiology highlighting important serotype shifts in different global regions in the PCV era. It also comprehensively summarizes newly discovered serotypes from 2007 to 2024, alongside updates on revised chemical structures and the de-novo determinations of structures for previously known serotypes. Furthermore, we spotlight emerging evidence on non-pneumococcal Mitis-group strains that express capsular PS that are serologically and biochemically related to the pneumococcal capsule types. We further discuss the implications of these recent findings on capsule nomenclature, pneumococcal carriage detection, and future PCV design. The review maps out the current status and also outlines the course for future research and vaccine strategies, ensuring a continued effective response to the evolving pneumococcal challenge.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1128/cmr.00175-24
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
